Yu Dan, An Guang Yu
Department of Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Evid Based Complement Alternat Med. 2017;2017:5936086. doi: 10.1155/2017/5936086. Epub 2017 Mar 28.
. To investigate the therapeutic effects of Xihuang pill combined with chemotherapy on advanced colorectal cancer. Sixty-three patients with advanced colorectal cancer were divided into an experimental group ( = 32) and control group ( = 31). Patients in the experimental group were treated with traditional Chinese medicine combined with Western medicine (i.e., Xihuang pill with FOLFOX or FOLFIRI chemotherapy), and those in the control group were treated with FOLFOX or FOLFIRI chemotherapy alone. Changes in therapeutic efficacy, side effects, blood coagulation function, and quality of life (QOL) were compared between the two groups. . The response rate was higher in the experimental than control group ( = 0.011). The QOL score in the experimental group was significantly lower after treatment than before treatment ( = 0.003), while no significant change was found in the control group. In the experimental group, the posttreatment activated partial thromboplastin time and prothrombin time after treatment were 30.05 ± 3.85 and 10.40 ± 1.25 s, respectively, which were prolonged compared with those before treatment (29.12 ± 4.03 and 9.85 ± 1.00 s; = 0.010 and 0.021, respectively). . In patients with advanced colorectal cancer, Xihuang pill combined with chemotherapy can significantly enhance the therapeutic effects compared with chemotherapy alone and improve patients' QOL and hypercoagulability.
观察西黄丸联合化疗治疗晚期结直肠癌的疗效。将63例晚期结直肠癌患者分为实验组（n = 32）和对照组（n = 31）。实验组患者采用中西医结合治疗（即西黄丸联合FOLFOX或FOLFIRI化疗），对照组患者仅采用FOLFOX或FOLFIRI化疗。比较两组患者的治疗效果、副作用、凝血功能及生活质量（QOL）的变化。实验组的缓解率高于对照组（P = 0.011）。实验组治疗后的QOL评分显著低于治疗前（P = 0.003），而对照组未发现显著变化。实验组治疗后活化部分凝血活酶时间和凝血酶原时间分别为30.05±3.85和10.40±1.25秒，与治疗前相比延长（分别为29.12±4.03和9.85±1.00秒；P分别为0.010和0.021）。对于晚期结直肠癌患者，西黄丸联合化疗与单纯化疗相比可显著提高治疗效果，并改善患者的QOL及高凝状态。
